Treatment persistence: A comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents

Journal of Clinical Pharmacy and Therapeutics

Volumn 31, Issue 1, 2006, Pages 57-65

  Ren, X S ^a,b   Qian, S ^a,b   Lee, A F ^a,b,c   Herz, L ^b,d   Miller, D R ^a,b   Kazis, L E ^a,b  

^a BOSTON UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Boston University   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atypical antipsychotic agents; Schizophrenia; Treatment persistence

Indexed keywords

ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RISK ASSESSMENT; SCHIZOPHRENIA; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME; VETERANS;

EID: 33645113415     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2006.00711.x     Document Type: Article

References (33)

1. Regier DA Narrow WE Rae DS Manderscheid RW Locke BZ Goodwin FK 1993 The de facto mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services Archives of General Psychiatry 50 85 94
2. Kane JM 1996 Drug therapy: schizophrenia New England Journal of Medicine 334 34 41
3. Andreasen NC Arndt S Alliger R Miller D Flaum M 1995 Symptoms of schizophrenia: methods, meanings, and mechanism Archives of General Psychiatry 52 341 351
4. Andreason N 1995 Symptoms, signs, and diagnosis of schizophrenia The Lancet 346 477 481
5. Murray CJL Lopez AD 1996 Summary: the global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020 Cambridge, MA Harvard University Press
6. Dickey B Wagenaar H Stewart A 1996 Using health status measures with the seriously mentally in health services research Medical Care 34 112 116
7. Atkinson M Zibin S Chuang H 1997 Characterizing quality of life among patients with chronic mental illness: a critical examination of the self-report methodology American Journal of Psychiatry 154 99 105
8. Dixon L Goldberg R Lehman A McNary S 2001 The impact of health status on work, symptoms, and functional outcomes in severe mental illness Journal of Nerves and Mental Disorder 189 17 23
9. Dixon L Postrado L Delahanty J Fischer PJ Lehman A 1999 The association of medical comorbidity in schizophrenia with poor physical and mental health Journal of Nerves and Mental Disorder 187 496 502
10. Green M 1996 What are the functional consequences of neurocognitive deficits in schizophrenia American Journal of Psychiatry 153 321 330
11. Hirsch SR Kissling W Bauml J 2002 A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia Journal of Clinical Psychiatry 63 516 523
12. Kane JM Carson WH Saha AR 2002 Efficacy and safety of aripiprazole and haloperidol vs. placebo in patients with schizophrenia and schizoaffective disorder Journal of Clinical Psychiatry 63 763 771
13. Purdon SE Jones BD Stip E 2000 Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for Research in Schizophrenia Archives of General Psychiatry 57 249 258
14. Vanelli M Burstein P Cramer J 2001 Refill patterns of atypical and conventional antipsychotic medications at a national retail pharmacy chain Psychiatric Services 52 1248 1250
15. Menzin J Boulanger L Friedman M 2003 Treatment adherence associated with conventional and atypical antipyschotics in a large state Medicaid program Psychiatric Services 54 719 723
16. Tafesse E Carson W 2003 Atypical antipsychotic adherence and hospitalization in patients with schizophrenia Schizophrenia Research 60 346
17. Veterans Health Administration 2002 Effective treatment for schizophrenia Practice Matters 7 2 5
18. Allison DB Mentore JL Heo M Chandler LP Cappelleri JC Infante MC Weiden PJ 1999 Anti-psychotic-induced weight gain: a comprehensive research synthesis American Journal of Psychiatry 156 1686 1696
19. Chakos M Lieberman J Hoffman E Bradford D Sheitman B 2001 Effectiveness of second-generation anti-psychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials American Journal of Psychiatry 158 518 526
20. Zhu B Gibson PJ Ascher-Svanum H 2003 A comparison of adherence and persistence levels among schizophrenia patients treated with atypical antipsychotics Schizophenia Research 60 349
21. Cramer JA Rosenheck P 1999 Enhancing medication compliance for people with serious mental illnesses Journal of Nervous and Mental Disorder 187 53 55
22. Dolder CR Lacro JP Dunn LB 2002 Antipsychotic medication adherence: is there a difference between typical and atypical agents? American Journal of Psychiatry 159 103 108
23. Ren XS Lee AF Huang YH 2004 Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia Journal of Clinical Pharmacy and Therapeutics 29 471 481
24. Bagnall AM Jones L Ginnelly L 2003 A systematic review of atypical antipsychotic drugs in schizophrenia Health Technol Assess 7 128 129
25. Ayuso-Gutierrez J Vega J 1997 Factors influencing relapse in the long-term course of schizophrenia Schizophrenia Research 28 199 206
26. Svarstaad BL Shireman TI Sweeney JK 2001 Using drug claims data to assess the relationship of medication adherence with hospitalization and costs Psychiatric Services 52 805 811
27. Grogg A Eaddy M Mauch R 2002 Effects of antipsychotic partial compliance on resource utilization in a schizophrenia and bipolar population Abstract presented at the 54th Annual Meeting of the Institute of Psychiatric Services Chicago, IL American Psychiatric Association
28. Kinon BJ Liu SH Hill AL Edwards SB 2003 Superiority of olanzapine vs. quetiapine in improving overall functioning in patients with schizophrenia Biological Psychiatry 53 69S 75S
29. Allison PD 1989 Event history analysis: regression for longitudinal event data Newbury Park Sage Publications
30. Lamoreaux J 1996 The organizational structure for medical information management in the department of veterans affairs: an overview of major health care databases Medical Care 34 MS31 MS44
31. Leslie DL Rosenheck RA 2001 Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors Medical Care 39 923 933
32. Ren XS Lee A Huang YH Lee AF Miller DR Qian S Kazis LE 2005 Adjunctive use of atypical antipsychotics and anticholonergic drugs among patients with schizophrenia Journal of Clinical Pharmacy and Therapeutics 30 65 71
33. Ren XS Kazis LE Lee AF et al. 2005 Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia Schizophrenia Research 77 167 177